Key facts
- This page summarizes Garry E. Menzel's Form 3 filing for Adaptimmune Therapeutics PLC (ADAP).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 01 Jun 2023, 16:50.
Garry E. Menzel - 01 Jun 2023 Form 3 Insider Report for Adaptimmune Therapeutics PLC (ADAP)
- Reporting relationship
- Director
- Issuer ticker
- ADAP
- Reported as of
- 01 Jun 2023
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 01 Jun 2023, 16:50:44 UTC
- Prior SEC filing
- 17 May 2023
- Next SEC filing
- 15 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Garry E Menzel**
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Garry E. Menzel filed Form 3 for Adaptimmune Therapeutics PLC (ADAP) on 01 Jun 2023.
Change
- Previous filing in this sequence was filed on 17 May 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Additional SEC filing notes
Filing notes and footnotes
Ownership status
The filing reports no beneficially owned securities.